EA033231B1 - Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad - Google Patents
Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triadInfo
- Publication number
- EA033231B1 EA033231B1 EA201700138A EA201700138A EA033231B1 EA 033231 B1 EA033231 B1 EA 033231B1 EA 201700138 A EA201700138 A EA 201700138A EA 201700138 A EA201700138 A EA 201700138A EA 033231 B1 EA033231 B1 EA 033231B1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- treatment
- chronic
- patients
- aspirin
- treatment modality
- Prior art date
Links
Abstract
The invention relates to medicine, namely to otorhinolaryngology, allergology and pulmonology, and is intended for treatment of chronic polypoid rhinosinusitis in patients with aspirin (asthmatic) triad during their post-surgical period. The goal of the declared modality is to increase the effectiveness of treatment by reducing the risk of side effects induced by non-steroid anti-inflammation medications. The essence of the invention is as follows. Following surgical treatment, endonasal mometasone furoate therapy is conducted of paranasal sinuses administering a dose of 100 μg twice a day for a month; next, ketorolac is administered endonasally to the amount of 1.26 mg per dose, 2 – 4 doses per day up each nasal passage for at least two years.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201700138A EA033231B1 (en) | 2017-02-17 | 2017-02-17 | Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EA201700138A EA033231B1 (en) | 2017-02-17 | 2017-02-17 | Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad |
Publications (2)
Publication Number | Publication Date |
---|---|
EA201700138A1 EA201700138A1 (en) | 2018-08-31 |
EA033231B1 true EA033231B1 (en) | 2019-09-30 |
Family
ID=63287029
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201700138A EA033231B1 (en) | 2017-02-17 | 2017-02-17 | Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad |
Country Status (1)
Country | Link |
---|---|
EA (1) | EA033231B1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2403071C1 (en) * | 2009-09-03 | 2010-11-10 | Логина Наталия Алексеевна | Method of treating chronic recurring inflammatory diseases of nasal cavity and paranasal sinises by method of endonasal autolymphocyto therapy |
RU2410083C2 (en) * | 2003-04-16 | 2011-01-27 | Дей Фарма, Л.П. | Compositions and methods of treating rhinosinusitis |
US20160367774A1 (en) * | 2013-03-26 | 2016-12-22 | Optinose As | Nasal administration |
-
2017
- 2017-02-17 EA EA201700138A patent/EA033231B1/en not_active IP Right Cessation
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2410083C2 (en) * | 2003-04-16 | 2011-01-27 | Дей Фарма, Л.П. | Compositions and methods of treating rhinosinusitis |
RU2403071C1 (en) * | 2009-09-03 | 2010-11-10 | Логина Наталия Алексеевна | Method of treating chronic recurring inflammatory diseases of nasal cavity and paranasal sinises by method of endonasal autolymphocyto therapy |
US20160367774A1 (en) * | 2013-03-26 | 2016-12-22 | Optinose As | Nasal administration |
Non-Patent Citations (2)
Title |
---|
ЕРЕМЕНКО Ю.Е. и др. Десенситизация аспирином у пациентов с астматической триадой. Оториноларингология. Восточная Европа, 2016, том 6, № 1, с. 99-105 * |
КРЮКОВ А.И. и др. Принципы лечения аллергического ринита. Медицинский совет, 2013, №7, с. 42-47 * |
Also Published As
Publication number | Publication date |
---|---|
EA201700138A1 (en) | 2018-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
RS52471B (en) | Dosage regimen for the treatment of a traumatic brain injury with progesterone | |
HRP20140784T1 (en) | Glyx-13 for use in a method of treating refractory depression | |
JP2009530385A5 (en) | Administration of ketamine for the treatment of depression | |
PE20142319A1 (en) | MULTIPLE SCLEROSIS TREATMENT WITH A COMBINATION OF LAQUINIMOD AND GLATIRAMER ACETATE | |
EA201490279A1 (en) | KINURENIN-3-MONOXYGENASE INHIBITORS, PHARMACEUTICAL COMPOSITIONS AND METHODS OF THEIR USE | |
MY166890A (en) | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof | |
HRP20240034T1 (en) | Treatment of cardiovascular diseases | |
RU2017119230A (en) | TREATMENT OF PIGMENTAL DETROPHY OF THE RETAIL WITH N-ACETYLCYSTEINAMIDE | |
MX2014001088A (en) | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof. | |
RU2014141893A (en) | APPLICATION OF THE PYRAZOLE DERIVATIVE IN THE TREATMENT OF ACUTE ACTIONS OF CHRONIC OBSTRUCTIVE LUNG DISEASE | |
EA201491460A1 (en) | APPLICATION OF LACHINIMODA IN THE TREATMENT OF PATIENTS WITH CRONE'S DISEASE, WHICH ARE NOT EFFECTIVE THERAPY OF THE FIRST LINE ANTI-TNFα | |
HRP20192189T1 (en) | Dosage forms and therapeutic uses l-4-chlorokynurenine | |
WO2012079093A3 (en) | Dosage and administration of bispecific scfv conjugates | |
MX2018013715A (en) | Aqueous based capsaicinoid formulations, and treatment in combination with a corticosteroid. | |
JP2020516646A5 (en) | ||
MX2016006179A (en) | Aqueous based capsaicinoid formulations and methods of manufacture and use. | |
JP2016505050A5 (en) | ||
RU2012108144A (en) | ANTI-CANCER THERAPY DIRECTED AGAINST CANCER STEM CELLS AND CANCER FORMS RESISTANT TO TREATMENT BY MEDICINES | |
EA033231B1 (en) | Treatment modality of chronic polypoid rhinosinusitis in patients with aspirin triad | |
CN102178736B (en) | A kind of medicine for the treatment of nasal sinusitis | |
MX2018009867A (en) | Methods comprising fixed intermittent dosing of cediranib. | |
CL2018003270A1 (en) | A pharmaceutical composition comprising carboxylic acid to treat and prevent nasal congestion. | |
MX2018005298A (en) | Dosage regimen for a phosphatidylinositol 3-kinase inhibitor. | |
TN2016000179A1 (en) | Dosage regimen for an alpha-isoform selective phosphatidylinositol 3-kinase inhibitor. | |
Jensen et al. | Onset of treatment response to a once-daily gastroretentive formulation of gabapentin in patients with postherpetic neuralgia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MM4A | Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s) |
Designated state(s): AM AZ BY KZ KG TJ TM RU |